ClinicalTrials.gg
Active, not recruitingNCT06106594Updated Oct 30, 2026

VOLT CE Mark Study

An interventional study of Pulsed Field Ablation in Atrial Arrhythmia, Atrial Fibrillation and Paroxysmal Atrial Fibrillation, sponsored by Abbott Medical Devices. Active, not recruiting at 11 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-30.

Sponsored by Abbott Medical Devices (part of Abbott) · Not applicable, Interventional, and Treatment

Updated Oct 30, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
300
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 70 studies in Atrial Fibrillation by Abbott — 3 open to participants now, 9 under way, none of them phase 3. Atrial Fibrillation · Abbott.

Planned enrollment
11th of 43
300 · median 200
Started
2023
with 1 other
No phase
39 of 70
3 open now
Registered
60th of 70
by date

Among the 70 studies in Atrial Fibrillation by Abbott, this one is the 11th largest by planned enrollment of the 43 interventional ones that give a count, is one of 2 that started in 2023, is one of 39 with no phase, and was the 60th registered.

Atrial Fibrillation

4,016 studies on the registry are indexed under Atrial Fibrillation; 964 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

3 of the 70 studies in Atrial Fibrillation by Abbott are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 610 Atrial Fibrillation studies recruiting now, 407 (67%) set no upper age limit and 43 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 70 studies in Atrial Fibrillation by Abbott, or all of them as a file.
02

Study summary

This clinical investigation is intended to demonstrate safety and effectiveness of the Volt™ Pulsed Field Ablation (PFA) Catheter Sensor Enabled™, the Volt™ PFA Generator, Agilis™ NxT Steerable Introducer Dual-Reach™, and EnSite™ X EP System EnSite™ Pulsed Field Ablation Module (for simplicity of reference this device collection will hereafter be referred to as the Volt™ PFA system) for the treatment of symptomatic, recurrent, drug-refractory paroxysmal and persistent atrial fibrillation.

Read the detailed description

The main study is a pre-market, prospective, single-arm, non-randomized, multicenter clinical study to demonstrate safety and effectiveness for the treatment of symptomatic, recurrent, drug-refractory Paroxysmal Atrial Fibrillation (PAF) and Persistent Atrial Fibrillation (PersAF). The main study design includes a feasibility sub-study in which additional imaging assessments will be collected in a small cohort of subjects to confirm acute safety of the Volt PFA System in humans.

The enrollment extension will include up to an additional 150 subjects enrolled with market-released or investigational devices, depending on enrollment geography.

03

Conditions studied

  • Atrial Arrhythmia
  • Atrial Fibrillation
  • Paroxysmal Atrial Fibrillation
  • Persistent Atrial Fibrillation

Browse trials for

Keywords

  • Atrial Arrhythmia
  • Pulsed Field Ablation
  • Paroxysmal AF
  • PFA
  • Persistent Atrial Fibrillation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Documented symptomatic PAF or PersAF. Documentation requirements are as follows:

    Paroxysmal:

    • Physician's note indicating recurrent self-terminating AF with ≥ 2 episodes of PAF within the 6 months prior to enrollment AND
    • One electrocardiographically documented PAF episodes within 12 months prior to enrollment.

    Persistent: Continuous AF sustained beyond 7 days and less than 1 year that is documented by

    • Physician's note, AND either
    • 24-hour Holter within 180-days prior to enrollment, showing continuous AF, OR
    • Two (from any form of rhythm monitoring) showing continuous AF:

      • That are taken at least 7 days apart but less than 12 months apart
      • If electrograms are more than 12 months apart, there must be one or more Sinus Rhythm recordings in between or within 12 months prior to consent/enrollment
      • The most recent electrocardiogram must be within 180 days of enrollment.

    NOTE: Documented evidence of the AF episode must either be continuous AF on a 12-lead ECG or include at least 30 seconds of AF from another ECG device.

  2. Plans to undergo a PVI catheter ablation procedure due to symptomatic PAF or PersAF and is , intolerant, or to at least one Class I-IV AAD medication
  3. At least 18 years of age
  4. Able and willing to comply with all trial requirements including pre-procedure, post- procedure, and follow-up testing and requirements
  5. Informed of the nature of the trial, agreed to its provisions, and has provided written as approved by the Institutional Review Board/Ethics Committee (IRB/EC) of the respective clinical trial site.

Exclusion criteria

Exclusion Criteria:

  1. Previously diagnosed long-standing persistent atrial fibrillation (AF greater than 1 year in duration)
  2. Arrhythmia due to reversible causes including thyroid disorders, acute alcohol intoxication, electrolyte imbalance, severe untreated sleep apnea, and other major surgical procedures in the preceding 90 days
  3. Participant known to require ablation beyond PVI at the time of consent (Main study only)
  4. Known presence of cardiac thrombus
  5. Left atrial diameter ≥ 5.5 cm (anteroposterior diameter)
  6. \< 35% as assessed with echocardiography within 180 days of index procedure
  7. (NYHA) class III or IV heart failure
  8. > 40 kg/m2
  9. Pregnant, nursing, or planning to become pregnant during the clinical investigation follow-up period
  10. Patients who have had a ventriculotomy or atriotomy within the preceding 28 days of procedure,
  11. Myocardial infarction (MI), acute coronary syndrome, percutaneous coronary intervention (PCI), or valve or coronary bypass grafting surgery within preceding 90 days
  12. Unstable angina
  13. Stroke or (transient ischemic attack) within the last 90 days
  14. Heart disease in which corrective surgery is anticipated within 180 days after procedure
  15. History of blood clotting or bleeding abnormalities including thrombocytosis, thrombocytopenia, bleeding diathesis, or suspected anti-coagulant sate
  16. to long term anti-thromboembolic therapy
  17. Patient unable to receive heparin or an acceptable alternative to achieve adequate anticoagulation
  18. Known sensitivity to contrast media (if needed during the procedure) that cannot be controlled with pre-medication
  19. Previous left atrial surgical or catheter ablation procedure (including LAA closure device)
  20. Presence of any condition that precludes appropriate vascular access
  21. Severe mitral regurgitation (regurgitant volume ≥ 60 mL/beat, regurgitant fraction ≥ 50%, and/or effective regurgitant orifice area ≥ 0.40cm2).
  22. Previous tricuspid or mitral valve replacement or repair
  23. Patients with prosthetic valves
  24. Patients with a myxoma
  25. Patients with an interatrial baffle or patch as the transseptal puncture could persist and produce an iatrogenic atrial shunt
  26. Stent, constriction, or stenosis in a pulmonary vein
  27. Rheumatic heart disease
  28. Hypertrophic cardiomyopathy
  29. Diagnosed with amyloidosis or atrial amyloidosis
  30. Active systemic infection
  31. Renal failure requiring dialysis
  32. Severe pulmonary disease (e.g., restrictive pulmonary disease, constrictive or ) or any other disease or malfunction of the lungs or respiratory system that produces severe chronic symptoms
  33. Presence of an implantable therapeutic cardiac device including permanent pacemaker, biventricular pacemaker, or any type of implantable cardiac defibrillator (with or without biventricular pacing function) or planned implant of such a device for any time during the follow-up period. Presence of an implantable loop recorder is acceptable as long as it is removed prior to insertion of the device.
  34. Presence of an implanted LAA closure device or plans to have an LAA closure device implanted during the follow-up period
  35. Patient is currently participating in another clinical trial or has participated in a clinical trial within 30 days prior to screening that may interfere with this clinical trial without pre-approval from this study Sponsor
  36. Unlikely to survive the protocol follow up period of 12 months
  37. Presence of other medical, anatomic, comorbid, social, or psychological conditions that, in the investigator's opinion, could limit the subject's ability to participate in the clinical investigation or to comply with follow-up requirements, or impact the scientific soundness of the clinical investigation results.
  38. Individuals without legal authority
  39. Individuals unable to read or write
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
300 participants (estimated)

Study arms

  • Experimental
    Volt PFA Catheter Sensor Enabled (SE)

    Device: Pulsed Field Ablation

Interventions

  • DevicePulsed Field Ablation

    Pulsed field ablation using the Volt PFA System

06

What researchers measure

Primary outcomes

  1. Rate of subjects experiencing a device and/or procedure-related serious adverse event with onset within 7-days of any ablation procedure that uses the Volt PFA System.

    Serious adverse events are defined as: * Atrio-esophageal fistula * Cardiac tamponade/perforation * Death * Heart block * Myocardial infarction * Pericarditis * Phrenic nerve injury resulting in permanent diaphragmatic paralysis * Pulmonary edema * Pulmonary vein stenosis * Stroke/cerebrovascular accident * Thromboembolism * Transient ischemic attack * Vagal nerve injury/gastroparesis * Major vascular access complications / major bleeding events * Device and/or procedure related cardiovascular and/or pulmonary adverse event that prolongs hospitalization for more than 48 hours (excluding hospitalization solely for arrhythmia recurrence or non-urgent cardioversion)

    Time frame: 7-days

  2. Acute procedural effectiveness summarized as the rate of pulmonary veins treated with the Volt PFA system that are isolated at the end of the index ablation procedure.

    Acute procedural failure for each pulmonary vein is defined as any of the following: 1. Inability to isolate a pulmonary vein at the end of the index ablation procedure. Isolation will be assessed via confirmation of electrical isolation in each ablated pulmonary vein after a minimum waiting period of 20 minutes via entrance block at a minimum. Touch-up ablation to achieve isolation will be allowed for any pulmonary vein reconnection detected during the index procedure with the investigational catheter (to the maximum delivery allowed per vein) and will not be considered a failure. 2. Any use of a non-study ablation device for pulmonary vein isolation.

    Time frame: During procedure

  3. Long-term 6-month effectiveness summarized as the rate of freedom from documented AF/AFL/AT episodes of >30 seconds duration after the index ablation procedure through 6 months of follow-up.

    The situations in which subjects will be considered long-term effectiveness endpoint failures: * Acute procedural failure * Any use of a non-study ablation device for pulmonary vein isolation or to deliver ablation lesions in the left atrium during the index procedure or during the first repeat procedure. * If documented AF/AFL/AT recurrence occurs at any time after the blanking period * If subject requires a repeat procedure for the treatment of AF, non-CTI-dependent AFL, or AT after the blanking period or a second repeat AF ablation procedure at any time after the index ablation procedure. * Any use of a new class I or III AAD for AF after the blanking period. * Any use of a class I or III AAD for AF at a dose higher than the historical maximum dose for the subject after the blanking period. * If the subject requires a cardioversion for the treatment of AF/AFL/AT after the blanking period * Surgical treatment of AF/AFL/AT post index procedure.

    Time frame: 6 months

07

Study locations

11 sites
08

References and documents

Publications

  • Tilz RR, Chierchia GB, Gunawardene M, Sanders P, Haqqani H, Kalman J, Healy S, Purerfellner H, Neuzil P, Asensi JO, Loh P, Reddy VY, Knecht S, Jesser E, Dirckx N, Miller A, Walker D, Lakkireddy D. Safety and effectiveness of the first balloon-in-basket pulsed field ablation system for the treatment of atrial fibrillation: VOLT CE Mark Study 6-month results. Europace. 2025 Mar 28;27(4):euaf072. doi: 10.1093/europace/euaf072. PubMed 40163671 ↗
  • Sanders P, Healy S, Emami M, Kotschet E, Miller A, Kalman JM. Initial clinical experience with the balloon-in-basket pulsed field ablation system: acute results of the VOLT CE mark feasibility study. Europace. 2024 May 2;26(5):euae118. doi: 10.1093/europace/euae118. PubMed 38701222 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2023 (actual). Primary completion is estimated for Jan 2027, 39 months after the start.

Of 255 industry-sponsored interventional studies with no phase under Atrial Fibrillation, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 36. This study's planned 39 months is above that.

Counting every sponsor, half of 1,049 studies reached it within 33 months; a quarter within 18 and three quarters within 54.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 30, 2026: primary completion Jun 2026 → Jan 2027 and completion Dec 2026 → Jan 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 16, 2023
First posted
Oct 30, 2023
StartActual
Oct 24, 2023
Primary completionEst.
Jan 2027was Jun 2026
CompletionEst.
Jan 2027was Dec 2026
Last update
Oct 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Jun 2026→Jan 2027
Oct 30, 2026
Study completion
Dec 2026→Jan 2027
Oct 30, 2026
Show all 1 update
  1. Oct 30, 2026
    Primary completion Jun 2026→Jan 2027
    Study completion Dec 2026→Jan 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06106594
Responsible party
Sponsor
First posted
Oct 30, 2023
Start date
Oct 24, 2023
Primary completion
Jan 2027 (estimated)
Completion
Jan 2027 (estimated)
Last update
Oct 30, 2026

Study contacts

Kristin Ruffner
study director · Abbott

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion